Determination of imatinib intracellular uptake in leukocytes as a prognostic factor in cML therapy
Abstract
Background: Imatinib is the first target therapy for chronic myelogenous leukemia (CML). Response to imatinib treatment also depends on the uptake of the drug into the target cell by organic cation transporter 1 (OCT1). OCT1 activity determined by the uptake of 14C-imatinib (IUR) in isolated mononuclear cells (MNC) has already been linked with treatment response. It has been proposed that the OCT1 activity determination could provide a valuable tool for the prediction of treatment success in patients with CML. Methods: MNC and granulocytes (Gran) of a healthy volunteer were incubated with imatinib in the presence or absence of prazosin before and after Ficoll cell sorting. The cells were lysed with liquid nitrogen and extracted with organic solvents. The intracellular concentration (ci) of imatinib was determined by LC-MS/MS method. Results: We measured the highest IUR in Gran isolated prior to incubation with imatinib. There the ci was 10-fold higher than in other cells. With prazosin, significantly lower imatinib ci were observed in MNC (1.49 ± 0.11 vs. 17.8 ± 1.6 mg/L) and Gran (96.2 ± 2.2 vs. 191.2 ± 7.7 mg/L) incubated after cell sorting. We measured the highest absolute OCT1 activity in Gran (6.27 ± 0.66 ng imatinib/200000 cells). Conclusions: We developed a procedure for the measurement of imatinib uptake into the white blood cells, which is not based on the use of radioactively labelled compounds. By means of this test, we also hope to determine the correlation of OCT1 activity with treatment success in the population of Slovenian CML patients.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
